JPMorgan raises Natera target to USD 460 for Natera stock

Published on 10/19/2026 at 10:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JPMorgan lifted its target from USD 360 to USD 460 on October 14, 2026. Natera stock costs EUR 352.15 on October 19, 2026.

Evidence and valuation markers

Natera announced 20 ESMO abstracts on October 18, 2026.
Second-quarter revenue reached USD 752.75 million, up 37.70 percent year over year.
Natera stock was trading at EUR 352.15 at 10:20 a.m. CEST at Lang & Schwarz on October 19, 2026.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) was trading at EUR 352.15 at Lang & Schwarz on October 19, 2026 at 10:20 a.m. CEST. JPMorgan raised its price target for the diagnostics company from USD 360 to USD 460 on October 14, 2026, while keeping an overweight rating, according to MarketBeat.

Twenty abstracts strengthen oncology evidence

Natera announced on October 18, 2026 that 20 abstracts featuring its technology will be presented at the European Society for Medical Oncology annual congress. The program includes Signatera Genome data and studies covering colorectal, breast, gastroesophageal and lung cancers, according to Business Wire.

The company said the newest Signatera Genome technology achieved an analytical limit of detection below 1 part per million. One study reported that Signatera results changed physicians' planned treatment for one in three patients, with 87 percent of those changes reducing treatment intensity.

What does the target change mean?

The higher target adds a sharper valuation reference after Natera's second-quarter revenue reached USD 752.75 million, up 37.70 percent from the year-earlier period. MarketBeat reported adjusted earnings per share of minus USD 0.47, compared with a consensus loss of USD 0.49, and quarterly revenue above the USD 661.24 million estimate.

Three dated steps before results

Natera's recent sequence runs from Citigroup raising its target from USD 365 to USD 480 on October 6, 2026, to JPMorgan lifting its target from USD 360 to USD 460 on October 14, 2026, and Natera announcing 20 ESMO abstracts on October 18, 2026. The target actions were reported by MarketBeat and the ESMO announcement by Business Wire.

Next dates for the evidence cycle

The ESMO Annual Congress is scheduled for October 23 through October 26, 2026, in Madrid, according to Business Wire. The presentations give investors a dated catalyst for assessing whether the new assay data can support broader clinical adoption.

Stock price and valuation context

Natera was trading at EUR 352.15 at Lang & Schwarz on October 19, 2026 at 10:20 a.m. CEST. The primary Nasdaq listing closed at USD 393.44 on October 16, 2026, while the 52-week range was USD 172.82 to USD 437.41, according to the quoted market context.

The further course of trading is shown by the continuously updated real-time quote of Natera stock.